{"schema_version":"secwatch.filing_event.v1","accession":"0000899923-22-000009","form_type":"8-K","ticker":"MYGN","cik":"0000899923","company_name":"MYRIAD GENETICS INC","filed_at":"2022-01-11T23:59:59+00:00","discovered_at":"2026-05-14T18:04:10.259309+00:00","generated_at":"2026-06-27T19:08:42.275941+00:00","sec_items":["2.02","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.4,"calibrated_materiality_score":0.4,"confidence":"medium","headline":"Myriad Genetics expects ~$400M cash on hand, no debt entering 2022","bullets":["CEO Paul Diaz presented at 40th Annual J.P. Morgan Health Care Conference on Jan 11, 2022.","Company expects to start 2022 with approximately $400M in cash, cash equivalents, and marketable securities.","Preliminary unaudited FY2021 financial data not finalized; adjustments could be material.","Company reports no debt, highlighting strong liquidity position."],"urls":{"canonical":"https://secwatch.observer/filing/0000899923-22-000009","json":"https://secwatch.observer/filing/0000899923-22-000009.json","markdown":"https://secwatch.observer/filing/0000899923-22-000009.md","text":"https://secwatch.observer/filing/0000899923-22-000009.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/899923/000089992322000009/0000899923-22-000009-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/899923/000089992322000009/mygn-20220111.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-27T19:08:42.275941+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}